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Background:Unregulatedcellproliferationorgrowthisaprominentcharacteristicofcancer.Wehavepreviously
demonstratedthatLMPs(cellmembranemicroparticlesderivedfromapoptotichumanCEMTlymphomacells
stimulatedwith actinomycin D) strongly suppress the proliferation of not only human endothelial cells but also
mouse Lewis lung carcinoma cells.
Methods: LMPs were generated either from CEM T cells using different stimuli or from 3 different types of
lymphocytes. The effects of LMPs on cancer cell proliferation were examined using cell lines from different
species and tissues. The cell cycle kinetics was evaluated by FACS and the expression of cell cycle-related
genes was determined using quantitative RT-PCR. The in vivo anti-tumor effect of LMPs was investigated
using xenografts and allografts.
Results: LMPs at doses far above physiological levels dramatically suppressed the proliferation of cancer cells
in a non species-specific manner. LMPs selectively target high proliferating cells and their anti-proliferative
effect is not dependent on parental cell origin or stimuli. The anti-proliferative effect of LMPs was due to
induction of cell-cycle arrest in G0/G1, with associated increases in expression of the cyclin-dependent kinase
inhibitors p15
INK4b, p16
INK4a, and p21
Cip1. In vivo, LMPs significantly suppressed tumor growth in animal
tumor models.
Conclusion: These results highlight the potential role of LMPs in modulating the growth of high proliferating
cells. Given that cell-based therapies are considered less toxic than pharmacologic approaches and have the
potential to target multiple pathways in a synergistic manner, LMPs may serve as averitable option for cancer
treatment.
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M
icroparticles are membrane-derived vesicles
(0.1 1 mm in diameter) that are released from
all eukaryotic cells during biological processes
of considerable diversity. Microparticles represent more
than just a miniature version of the specific cell of origin,
as certain components of microparticles are selectively
enriched compared to their parent cell. The composition
and function of microparticles depends not only on the
cellular origin but also on the agonist responsible for their
formation (1). Mounting evidence has recently revealed
that microparticles constitute protagonists of a communi-
cation network for the intercellular exchange of biological
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associated with vascular dysfunction and alterations in
homeostatic parameters (1).
Lymphocyte-derived microparticles (LMPs), generated
by actinomycin D treatment of human CEM T cells
or circulating LMPs isolated from either diabetic or
HIV-positive patients, impair endothelial function and
vascular contraction (2,3). The proteomic analysis re-
vealed that LMPs display a broad spectrum of bioactive
substances and receptors on their surface (4). Regarding
the effects of LMPs on angiogenesis, controversial results
are reported (5 7), which is possibly caused by the
different stimulation at their origin (7).
Proliferation and angiogenesis are crucial steps in
tumour growth. In addition to the anti-angiogenic effect
of LMPs, we have observed that LMPs strongly suppress
tumour growth, cell proliferation in the animal models of
Lewis lung carcinoma (LLC) (6). It is well known that
proliferation of mammalian cells is regulated by com-
plexes of cyclins and cyclin-dependent kinases (CDKs),
and the activity of CDKs can be limited by specific cyclin-
dependent kinase inhibitors (CDKIs) (8,9). The deregula-
tion of CDKs is widespread in cancer cells (10,11).
Nonetheless, the role of LMPs in cancer is poorly under-
stood. This study was designed to characterize the anti-
proliferation effect of LMPs on various cancer cell types
using LMPs generated from different stimuli and from
lymphocytesofdifferentorigin.WefoundthatLMPsexert
anti-proliferative and anti-tumour effects in vitro and in
vivo. These inhibitory effects operated across species lines
and were not specific to tumour type or stimuli. On the
molecular level, LMPs specifically induce cancer cells
arrest in G1 phase associated with the upregulation of
CDKIs expression.
Materials and methods
Cell lines and cell proliferation assay
Immortalized rat retinal ganglion cells (RGC-5) were
kindly provided by Neeraj Agarwal (University of North
TexasHealthScienceCenter).RGC-5cellswereinducedto
differentiate in serum-free medium with 1.0 mM stau-
rosporine (12,13). Cell lines were purchased from Applied
Cell Biology Research Institute   human retinal endothe-
lial cells (HRECs), and from American Type culture
collection (ATCC, Manassas, VA)   mouse LLC, mouse
neuroblastoma(N2a),humanneuroblastoma(SH-SY5Y),
HeLa, human breast cancer (M4A4, MCF-7, MDA-MB-
231), lung carcinoma (H460), CEM T cell and Jurkat T
lymphoma. Cells were maintained according to their
recommendations.
Cell proliferation was evaluated by [
3H]-thymidine
incorporation assay as previously described (6). Assays
were performed 24 hours after LMPs treatment, unless
otherwise indicated.
Primary cell culture
Rat cortical neurons were isolated from adult Sprague-
Dawley rats as described elsewhere (14). Briefly, cortices
were cleaned from their meninges and blood, and then
minced and dissociated with trypsin, followed by adding
DNase I and soybean trypsin inhibitor (Sigma), and
triturated through a 5 mL pipet. After the tissue was
settled, the supernatant was collected, and the remaining
tissue pellet was retriturated. The combined supernatants
were then centrifuged through a 4% BSA layer and the
cell pellet was resuspended in neuronal seeding medium.
Isolated cells were resuspended in neuronal seeding
medium which consisted of neurobasal medium (Gibco),
supplemented with 1.1% 100 antibiotic antimycotic
solution (Biofluids), 25 mM Na glutamate, 0.5 mM L-
glutamine and 2% B27 Supplement (Gibco). Cells were
seeded at a density of 1.5 10
5 cells onto each well of 24-
well tissue culture plates (Corning) pre-coated with poly-
D-lysine(70 150kD,Sigma).Cellswereseededatadensity
of 1.5 10
5 cells per well in 24-well plates pre-coatedwith
poly-D-lysine. Fully confluent cells were treated with
LMPs for 24 hours.
Human retinoblastoma cells were isolated from a pri-
mary site intraocular retinoblastoma from a 2-year-old
female Caucasian patient. In accordance with the CHU
Sainte-Justine Ethics Committee, the specimen was ob-
tained with the donor’s informed consent and with the
understanding that part of the tumour would be used
for research purposes. A 50 mg retinoblastoma specimen
(pathologically confirmed) was minced and subjected to
collagenase enzymatic digestion. After the digestion, a
low-speed centrifugation was performed to eliminate
fibroblasts in the upper layer. A total of 25 10
4 cells
were subsequently isolated and cultured in RPMI-1640
medium with 10% FBS and penicillin streptomycin L-
glutamine. Retinoblastoma cells were characterized for
syntaxin expression by fluorescence-activated cell sorting
(FACS) using anti-human syntaxin-FITC (Cedarlane,
Canada) (15).
LMPs production
CEM T, Jurkat T lymphoma cells (ATCC, Manassas, VA)
and human peripheral T cells were cultured in X-VIVO
medium (Cambrex, Walkersville, MD). As described
previously, LMPs were produced by stimulating T cells
with actinomycin D (0.5 mg/mL) for 24 hours (5). A super-
natant was obtained by centrifugation at 750 g for 15 min,
then 1,500 g for 5 minutes to remove cells and large debris.
LMPs from the supernatant were washed after 3 centri-
fugation steps (50 minutes at 12,000 g) and recovered
in PBS. As washing medium from the last supernatant
has been widely used as control vehicle for each indivi-
dual microparticle (2,7,16,17), this particular medium was
used as a control in following experiments unless other-
wise noted. 1 10
6 T cells stimulated with actinomycin
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of LMPs. To investigate whether heat-denatured LMPs
are good control for LMPs, we performed cell growth
assay and found that heat-denatured LMPs still possess
40% effectiveness of inhibiting endothelial cell growth
(unpublished data). Using the same protocol, we also
generated LMPs from hyperoxia- (95% O2, 36 hours) and
hypoxia- (5% O2, 36 hours) exposed T cells. Human
peripheral blood lymphocytes were prepared using Ficoll-
Hypaque gradient centrifugation (18) and T cell popula-
tions were purified with Pan T Cell Isolation Kit II
(Miltenyi Biotec). LMPs were characterized with annexin
V staining by FACS analysis and gated using 1.0-mm
beads in which 97% of MPs (51 mm) were annexin-V-Cy5
positive. The concentrations of LMPs were determined
using the Bio-Rad protein assay.
Analysis of cell cycle kinetics
LLC cells in log phase of growth were exposed to basal
media in the absence or presence of 10 mg/mL LMPs for
24 hours. Cells were harvested and stained with propi-
dium iodide (Molecular Probes) and subjected to FACS
analysis. The distribution of cells in G0/G1, S and G2/M
phases was determined using LYSIS II software (Becton
Dickinson).
RNA isolation and quantitative RT-PCR
Total RNA from monolayer LLC cells was extracted and
cDNA was synthesized and amplified as previously
reported (19). Primers for p15
INK4b, p16
INK4a, p21
Cip1,
CDK2, CDK4 and mouse 18S rRNA were synthesized
(Invitrogen) as follows (20): p15
INK4b: forward 5?-AAG
CACCTTTGCTGCCTCC-3?, reverse 5?-GCAGCACGA
CAAGCCTGTCC-3?; p16
INK4a: forward 5?-ACGGTG
CAGATTCGA ACTG-3?, reverse 5?-TACACAAAGAC
CACCCAGCG-3?; p21
Cip1: forward 5?-GAGCCACAGG
CAC CATGTCC-3?, reverse 5?-AGACCTTGGGCAGC
CCTAGC-3?; CDK2: forward 5?-TGGGCTGCAAGTAC
TACTCC-3?, reverse 5?-TTGTGATGCAGCCACTTCTA-
3?; CDK4: forward 5?-TTGTACG GCTGATGGATG-
3?, reverse 5?-CGGTCCCATTACTTGTCAC-3?; mouse
housekeeping 18S rRNA was used as internal control,
forward 5?-AGGGGAGAGCGGGTAAGAGA-3?,r e -
verse 5?-GGACAGGACTAGGCGGAACA-3?. PCR am-
plification protocol involved 40 cycles of denaturation at
958C for 30 seconds, primer annealing at 558C and primer
extension at 728C for 1 minute. Each sample was analyzed
in triplicate. The mRNA levels of each gene were quan-
tified relative to 18S and the fold change in gene
expression in control and LMPs-treated samples was de-
termined according to the equation: fold change 2
 DCt,
where DCt (Ct)Experimental (Ct)Control.
Western blot analysis
LLC cells were collected after LMPs treatment for 24
hours. Extraction of soluble proteins and fractionation by
SDS-PAGE was performed as described previously (5).
The anti-p15, anti-p16 and anti-p21 antibodies (LifeSpan
BioSciences, Inc. 1:500) were used to reveal the protein
levels of p15
INK4b, p16
INK4a and p21 Cip1, respectively.
b-Actin was used as a loading control. Proteins were
visualizedusingtheECLwesternblottingdetectionsystem
(PerkinElmer, Inc.). Densitometry values were measured
in terms of pixel intensity by Fluorchem software.
Animal experiments
Female athymic nude mice and C57BL/6 mice (5 7 weeks
old) were purchased from Charles River Laboratories
International, Inc. (St-Constant, Quebec, Canada.) and
used for xenografting and allografting, respectively,
according to protocols approved by the CHU Sainte-
Justine Animal Care Committee. The weight and general
appearance of the animals were recorded every other day
throughout the experiments.
Neuroblastoma xenografts and intratumoural
injection of LMPs
Mice were subcutaneously injected with human neuro-
blastoma cells (SH-SY5Y, 20 10
6 cells in 0.1 mL
of PBS) in the right flank. When tumours reached
 100 mm
3, mice were randomized to receive 7 con-
secutive intratumoural injections of either 50 mL control
vehicle or 2.5 mg/kg LMPs every 2 days. Tumour weights
were determined at the conclusion of the treatment.
Allograft tumour growth and intravenous injection
of LMPs
Allograft animal models were generated as previously
described (6). Briefly, 10 days after LLC inoculation, mice
were randomly grouped to receive intravenous injection:
control group   100 mL control vehicle; treatment group  
50 mg/kg LMPs (in 100 mL PBS, optimal dose had been
tested) every 2 days for 4 consecutive injections. Micewere
weighted, and tumour size was measured and recorded
every 2 days with an electronic calliper. Tumour volume
was estimated based on the formula: Tumour volume 
length (mm) width
2(mm
2)/2. Mice were sacrificed 18
days post-LLC inoculation, and primary tumours were
snap frozen.
Breast cancer xenografts and tumour explants. Human
breast cancer xenografts were generated by subcuta-
neously inoculating mice with 2 10
6 M4A4 cells.
Tumours were removed within 4 weeks of growth and
sliced into pieces of 1 2 mm in diameter. Tumour
explants were cultured on Matrigel (BD Biosciences) for
24 hours, as previously described (21), and subsequently
exposed to LMPs for different time periods.
Assessment of LMPs haematotoxicity
Six-week-old C57BL/6 mice received single intravenous
injections of 25 or 75 mg/kg of LMPs (approximately 10
and 30 times the IC50, respectively) or control vehicles
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activities, food consumption, skin colour, or fur was
performed. Thirty days after LMPs injection, animals
were euthanatized and tissues were examined for gross
pathology. Peripheral blood was collected and subjected
to a complete blood count.
Ki-67 immunohistochemical staining
The cell proliferation in LLC primary tumours was de-
termined using immunohistochemical staining of Ki-67
as described (22). Briefly, tumour tissues were fixed in
formalin and embedded in paraffin. Sections were cut at
4 mm and baked for 4 hours at 608C. Slides were depar-
affined in xylene and brought to water through graded
ethanol. An indirect immunoperoxidase staining was per-
formed with rabbit monoclonal anti-mouse Ki-67 (clone
SP6, Cell Marque, Rocklin, CA). Nuclear brown staining
was considered positive. Proliferation was quantified and
expressed as a proliferative index (PI) score, which was
determined as the mean percentage of nuclei staining
positive for Ki-67 antibody in 1,000 cells at 600 
magnification. Four non-overlapping high-power fields
that contained thehighest average fraction of labelled cells
for each tumour tissue were included in the calculation of
PI score. All counts were completed by a blinded fashion.
Breast tumour explants were frozen in OCT (Sakura),
sliced into 12 mm sections, fixed in 4% paraformaldehyde
and permeabilized in 1.0% Triton X-100. Sections were
then incubated with rabbit anti-Ki-67 antibody (1:200;
ab15580, Abcam), followed by incubation with a goat
anti-rabbit IgG conjugated to Alexa Fluor 488 (1:1,000;
Invitrogen). Cell nuclei were stained with DAPI. Sections
were observed with an epifluorescent microscope (Nikon
eclipse E800) and images were taken with a Nikon DXM
1200 camera. The PI was determined as described above.
Statistical analysis
All experiments were repeated at least 3 times and values
are presented as means9SEM. Data were analyzed by
Student’s t test, one-way or two-way ANOVA followed by
post-hoc Bonferroni tests for comparison among means.
Statistical significance was set at PB0.05.
Results
LMPs inhibit proliferation of cancer cells originating
from different tissues and species
We first examined the effects of LMPs on cancer cell
proliferation using cell lines from human breast cancers,
cervical cancer, lung carcinoma, and human and mouse
neuroblastoma. LMPs (5 and 10 mg/mL) significantly
inhibited the proliferation of all tested cell lines in a
concentration-dependent manner (Fig. 1A and B). LMPs
also suppressed the proliferation of human primary re-
tinoblastoma (Rb) cells, thus excluding the inference that
LMPs only target established cancer cell lines (Fig. 1B).
To determine whether these anti-proliferative effects were
LMPs specific, we incubated HRECs and LLC cells with
CEM T cells; 5 million T cells were equivalent to cell
numbers producing 10 mg/mL LMPs. After 24 hours, no
sustainable anti-proliferative effects were observed in cells
exposed to T cells (Fig. 1C).
LMPs induce cell-cycle arrest in G0/G1 phase
To elucidate the mechanisms underlying the anti-
proliferative effect of LMPs, we evaluated the cell cycle
kinetics of LLC cells by FACS. Relative to control, LMP-
treated cells exhibited an increase in G0/G1-phase time;
conversely, the proportion of LMPs-treated cells in G2/M
markedly declined (Fig. 2A and B). Gene expression
studies were then performed to help characterize specific
mechanisms of the cell-cycle alteration. Our results
showed that mRNA levels of the CDK inhibitors
p15
INK4b, p16
INK4a and p21
Cip1 were elevated by approxi-
mately 4-, 2.8- and 5.8-fold, respectively, after LMPs
treatment; mRNA levels of CDK4   a cell cycle regulator
  decreased by 42% (Fig. 2C). Moreover, LMPs sig-
nificantly augmented the protein levels of p15
INK4b,
p16
INK4a and p21
Cip1   as indicated by a 1.8-, 1.6- and
2.7-fold induction, respectively (Fig. 2D and E).
LMPs suppress tumour growth in animal models
The anti-tumour effect of LMPs was investigated in vivo
using human neuroblastoma xenografts and mouse LLC
allografts. Compared with control, tumour growth was
significantly reduced in LMPs-treated neuroblastoma
xenografts (Fig. 3A and B). The same is true for mouse
LLC allografts; the tumour volumes were significantly
decreased after intravenous injection of LMPs (Fig. 3).
No significant toxicity was observed in the mice that
received systemic injection of high doses of LMPs for 30
days (data not shown).
LMPs inhibit tumour cell proliferation in vivo and
ex vivo
To verify whether the anti-tumour activity of LMPs was
associatedwiththedecreasedtumourcellproliferation,we
performed immunostaining for Ki-67, a most commonly
used cell proliferation marker (23 25). There was a high
intensity of Ki67 staining in control untreated LLC
allografts, and LMPs’ treatment significantly decreased
the expression of Ki-67 (Fig. 4A and B). In the breast
tumour explants, the cell proliferation was decreased by
LMPs in a time-dependent manner (Fig. 4C and D).
The anti-proliferative effect of LMPs is independent
of stimuli or cell origin
Next, we questioned whether LMPs can impact the
proliferation of quiescent cells and terminally differen-
tiated cells. We therefore examined the effect of LMPs on
the growth of immortalized RGC-5 cells, staurosporine-
induced terminally differentiated RGC-5 cells (12)
Chun Yang et al.
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dependently suppressed the proliferation of immortalized
RGC-5 cells, they had no effect on the proliferation of
differentiated RGC-5 cells or quiescent cortical neurons
(Fig. 5A).
To explore whether the inhibitory effects of LMPs
were stimulus dependent, we evaluated the impact of
LMPs generated from CEM Tcells using different stimuli:
actinomycin D (induces apoptosis), phytohemagglutinin
(PhA; stimulates cell division), and hyperoxia and hypoxia
(trigger oxidative stress). LMPs produced under these
conditions potently suppressed LLC cell proliferation by
45 49% compared with control (Fig. 5B).
To examine whether the anti-proliferative effect of
LMPs was dependent on the parental cell origin, we
evaluated LLC cell proliferation using LMPs derived
from 3 types of lymphocytes: CEM T, JurKat and human
peripheral T lymphocytes. Our results show that all 3
sourcesofLMPs(producedbyactinomycinDstimulation)
exerted comparable effects on LLC cell proliferation
(Fig. 5C).
Discussion
In this report, we demonstrate for the first time that
LMPs exert strong anti-proliferative effects on various
cancer cells across species lines. These anti-proliferative
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Fig. 1. LMPs inhibit cancer cell proliferation. Indicated concentrations of LMPs generated from CEM T cells via actinomycin D
stimulation were added to: (A) human breast cancer cells (MCF-7, M4A4 and MDA-MB-231), HeLa cells; and (B) mouse (N2a) and
human (SH-SY5Y) neuroblastoma cells, human primary retinoblastoma (Rb) cells and human non-small-cell lung cancer (H460) cells.
(C) Human retinal endothelial cells (HRECs) and Lewis lung carcinoma (LLC) cells were treatedwith indicated concentrations of CEM
T cells. Relative cell proliferation rates were determined after 24 hours of LMPs treatment and presented as percentage of control (CTL
was set at 100%). *PB0.05, **PB0.01, ***PB0.001 vs. CTL.
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(page number not for citation purpose)effects are not limited to cancer cells but encompass
immortalized RGCs and high-proliferating endothelial
cells, as previously reported by us (5). Notably, LMPs
have little effect on terminally differentiated RGCs and
quiescent neurons, suggesting that they selectively target
high-proliferating cells, such as cancer cells and activated
endothelial cells. Anti-tumour effects of LMPs in vivo
were observed not only in neuroblastoma xenografts and
human breast cancer explants but also in LMPs-treated
LLC allografts (Fig. 3A). The anti-proliferative/anti-
tumour properties of LMPs were further corroborated
by a significantly reduced Ki-67 proliferation score in
LMPs-treated tumours.
Our further studies revealed that the anti-proliferative
effects of LMPs were associated with blocking of the cell
cycle at G0/G1. Consistent with this observation, expres-
sion of the CDK inhibitors p15
INK4b, p16
INK4a and
p21
Cip1 were increased in LMPs-treated cells, whereas
CDK4   a pivotal cell cycle regulator of G1/S transition  
was downregulated. Both p15
INK4b and p16
INK4a can
function as tumour suppressors (11,26). The p16
INK4a is
a specific inhibitor of CDK4 and potentially blocks G1
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Fig. 2. LMPs induce cell cycle arrest in G0/G1 phase and increase cyclin-dependent kinase (CDK) inhibitors. (A) Representative graphs
depicting cell-cycle progression in LLC cells treated with or without LMPs (10 mg/mL for 24 hours). (B) The percentage of cells in each
phase of the cell cycle was presented as means9SEM. The data were pooled from 4 independent experiments. (C) Gene expression in
LMPs-treated Lewis lung carcinoma cells was quantiﬁed relative to the housekeeping gene and presented as fold induction compared
with control (CTL). (D) LLC cells were treated with10 mg/mL LMPs for 24 hours, and CDK inhibitors p15
INK4b, p16
INK4a and p21
Cip1
expression was detected by western blot. (E) p15
INK4b, p16
INK4a and p21
Cip1 protein levels were normalized to b-actin, and the control
condition was set to equal 100%. Values are means9SEM of 3 experiments. *PB0.05, **PB0.01 vs. CTL. P15
INK4b, p16
INK4a and
p21
Cip1 are CDK inhibitors. CDK2 and CDK4 are protein kinases of CDK family.
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INK4b-mediated
pathways that control G1/S transition are frequently
deregulated in tumour cells. In addition, the p21
Cip1
arrests cells at the G1/S transition by reducing cyclin E/
CDK2 and CDK4 activity (29). Up to date, the mecha-
nisms underlying the anti-proliferative effect of LMPs
remain unclear. Although there is no evidence to support
the direct inhibitory mechanism due to the fact that no
cell cycle inhibitory proteins were identified from pro-
teomic analysis of LMPs (4), ours and other recent
studies strongly suggested that LMPs induce cell cycle
arrest through induction of oxidative stress and down-
regulation of VEGF signalling (5,6,30,31). A late experi-
ment indicated that proteins may not be the only caus-
ative components in LMPs, lipids or other heat-stable
components also contribute to the anti-cell growth effects
of LMPs (unpublished data).
It has been reported that the mode of cell activation
and the microenvironment where microparticles were
generated relevantly determines the nature of microparticle-
mediated intercellular communication (1). Although pre-
vious studies investigating the role of LMPs in angiogenesis
have yielded contradictory results, these conflicting angio-
genic responses are probably due to different modes
of stimulation of the parental lymphocytes (5,7,17,32).
Regarding the impact on cell growth, our data show that
the anti-proliferative effect of LMPs is not dependent on
lymphocyte origin or stimuli. This is evident from in vitro
studies whereby comparable anti-proliferative effects were
observed in LMPs produced from (a) lymphocytes of
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Fig. 4. LMPs inhibit tumour cell proliferation in vivo and ex
vivo. (A) Representative images of Ki-67 immunostaining of
parafﬁn-ﬁxed LLC tumour sections. Indirect immunoperoxidase
staining was performed with rabbit monoclonal anti-mouse Ki-
67. Arrows indicate Ki-67-positive cells, which exhibited brown
nuclei. Bar, 30 mm. (B) Cell proliferation was determined as the
mean percentage of Ki-67-positive nuclei per 1,000 cells. (C)
Representative pictures of Ki-67 immunostaining in human
breast cancer explants treated with or without LMPs. Green
ﬂorescence indicated the Ki-67-positive cells. (D) Graph illus-
trating the Ki-67 score for control (CTL) and LMP-treated cells.
*PB0.05, **PB0.01 vs. CTL.
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(page number not for citation purpose)different origin and (b) CEM T cells exposed to 3
different stimuli. To exclude the possibility of mycoplas-
ma contamination causing the observed effect of LMPs, a
sensitive PCR-based test was performed, and it proved
that LMPs and CEM T cells are mycoplasma free (data
not shown).
Having previously demonstrated that low-density lipo-
protein receptor (LDLR) plays a key role in mediating the
anti-VEGF effect of LMPs (6,31), we postulate that
LDLR also mediates the anti-proliferative effect of
LMPs. This inference is based on observations that high
LDLR activity has been linked to neoplastic cells and
proliferating endothelial cells (33 35), and that low
LDLR activity is associated with quiescent endothelial
cells (33). Nevertheless, we cannot exclude the involve-
ment of other membrane receptors or proteins in this
process. For example, the CD36 scavenger receptor has
been shown to mediate uptake of LMPs in brain micro-
vascular endothelial cells (unpublished data). Then again,
additional studies are required to elucidate how LMPs are
delivered into target cells, and to increase our under-
standing of the molecular biology of LMPs.
In recent years, bioactive compounds have emerged as
potential anticancer therapies. Edelman and colleagues
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Fig. 5. The anti-proliferative effect of LMPs is not dependent on stimuli or cell origin. (A) Depicted are cell proliferation rates of
immortalized retinal ganglion cells (RGC-5), staurosporine-induced terminally differentiated RGC-5 cells and rat cortical neurons after
24 hours of treatment with indicated concentration of LMPs. (B) Lewis lung carcinoma (LLC) cell proliferation was measured
following 24 hours exposure to LMPs produced from CEM T cells using different stimuli. (C) LLC cells were treated with LMPs
generated from CEM T, JurKat and human peripheral T lymphocytes using actinomycin D (ActD) stimulation. Cell proliferation is
presented as a percentage of control (CTL), which was set to 100%. Values are presented as means9SEM. ***PB0.001 vs. CTL.
Phytohemagglutinin (PhA).
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lial cells reduce the proliferative and invasive phenotype
of both lung and breast cancer cells (36). In addition,
Camussi’s group have provided evidence that microvesi-
cles derived from human bone marrow mesenchymal
stem cells inhibit tumour growth. The delivery of selected
miRNAs by microvesicles and activation of negative
regulators of cell cycle may explain these biological
effects (37,38). Moreover, multiple inhibition components
released from cancer cell containing agarose beads have
yielded profound effects on tumour growth in vivo.
Therefore, the synergistic effect of multiple components
helping to produce part of the effect is considered a
unique aspect of cellular therapy (39,40). Along these
lines, LMPs and bioactive compounds released from
macrobeads have several characteristics in common, they:
(a) are produced from living cells cultured under specific
conditions; (b) contain multiple factors, including pro-
teins with tumour inhibitory properties; and (c) exert
effects that are neither species- nor tumour-type specific.
Insummary,thisstudyhighlightsthepotentialofLMPs
to modulate growth of high-proliferating cells without
targeting quiescent cells. An increased understanding of
the multifaceted intrinsic regulatory mechanisms of
LMPs, their cell interactions and active components may
lead to the development of novel therapeutic strategies for
cancer treatment.
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